CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Aug. 31, 2025	Aug. 31, 2024
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenue	$ 705,923	$ 464,278
Cost of goods sold	2,720	4,822
Gross profit	703,203	459,456
Operating expenses
Research and development	8,238,757	2,360,565
General and administrative	4,345,183	3,852,021
Total operating expenses	12,583,940	6,212,586
Loss from operations	(11,880,737)	(5,753,130)
Other income (loss)
Interest income	3,017	14,311
Unrealized loss on marketable securities	(33,714)	(69,835)
Total other income (loss)	(30,697)	(55,524)
Net loss	(11,911,434)	(5,808,654)
Less: Net loss attributable to non-controlling interest	(9,593)	(13,309)
Net loss attributable to Lexaria shareholders	(11,901,841)	(5,795,345)
Other comprehensive income (loss)
Foreign currency translation adjustment	(50,519)	(19,816)
Total comprehensive loss	$ (11,952,360)	$ (5,815,161)
Basic and diluted loss per share	$ (0.66)	$ (0.47)
Weighted average number of common shares outstanding
- Basic and diluted	17,998,715	12,383,974